Abstract
In November, 1999, all children under age 18 years in the UK were offered immunisation with the newly introduced meningococcal C conjugate vaccine (MCCV). In a cohort of 106 patients with nephrotic syndrome, there were 63 relapses during the 12 months before vaccination, and 96 during the equivalent period postvaccination (p=0.009). The relapse rate of nephrotic syndrome increased significantly after administration of MCCV. Whether to vaccinate such children needs to be carefully considered.
Publication types
-
Comparative Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Ambulatory Care
-
Cytokines / adverse effects
-
Cytokines / immunology
-
Female
-
Humans
-
Male
-
Meningitis, Meningococcal / immunology
-
Meningitis, Meningococcal / prevention & control*
-
Meningococcal Vaccines / adverse effects*
-
Meningococcal Vaccines / therapeutic use*
-
Nephrotic Syndrome / drug therapy
-
Nephrotic Syndrome / etiology*
-
Nephrotic Syndrome / immunology*
-
Recurrence
-
Risk Factors
-
Vaccination / adverse effects*
Substances
-
Cytokines
-
Meningococcal Vaccines
-
serogroup C meningococcal conjugate vaccine